Literature DB >> 16330877

Transdifferentiation of endothelial and renal tubular epithelial cells into myofibroblast-like cells under in vitro conditions: a morphological analysis.

M Sommer1, J Gerth, G Stein, G Wolf.   

Abstract

Renal fibrosis is a hallmark of progressive kidney disease and is characterized by an accumulation of extracellular-matrix-synthesizing cells in the glomerulus and tubulointerstitium. This population of myofibroblast-like cells (MFLC) is heterogeneous. It has been experimentally shown, for example, that tubular epithelial cells could change their phenotype into MFLC under certain circumstances, a process called epithelial-mesenchymal transdifferentiation. However, MFLC may also originate from other sources. Therefore, we examined whether endothelial cells (EDC) are able to transdifferentiate into MFLC in vitro. We compared potential differences between syngeneic tubular epithelial cells (EPC) and EDC during transdifferentiation into MFLC using bovine and porcine EDC isolated from pulmonary arteries, and glomerular capillaries. Renal tubular EPC were prepared from bovine renal cortical tissue by collagenase digestion and isolation from homogeneous cell monolayers. Bovine renal tubular EPC stained positive for cytokeratin. Furthermore, tubular EPC selectively incorporated labeled bovine serum albumin, a typical property of differentiated renal tubular cells. EDC were characterized by the absence of epithelial markers (e.g. cytokeratin), but stained positive for vWF. The transdifferentiation of EDC into MFLC occurs sequentially in two steps: First, by a rapid reversible transformation in postconfluent or clonal cultures without the need of cytokine stimulation and second, by a prolonged secondary step in the presence of the transformation-accelerating cytokines and the absence of adherently growing EDC. Thus, EDC that are able to sprout can also irreversibly transdifferentiate into MFLC. On the other hand, prolonged incubation of EPC in the presence of cytokines such as transforming growth factor-beta1 and tumor necrosis factor-alpha leads only to a very small number of MFLC without the ability to further proliferate. Our in vitro data suggest that EDC can more easily transdifferentiate into MFLC than syngeneic renal tubular EPC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330877     DOI: 10.1159/000088937

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  5 in total

Review 1.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

2.  Role of TGF-β1/p38 MAPK pathway in hepatitis B virus-induced tubular epithelial-myofibroblast transdifferentiation.

Authors:  Changhong Liu; Fengzhe Chen; Xiaochun Han; Hui Xu; Yiguo Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.

Authors:  Federica Sotgia; Francesco Del Galdo; Mathew C Casimiro; Gloria Bonuccelli; Isabelle Mercier; Diana Whitaker-Menezes; Kristin M Daumer; Jie Zhou; Chenguang Wang; Sanjay Katiyar; Huan Xu; Emily Bosco; Andrew A Quong; Bruce Aronow; Agnieszka K Witkiewicz; Carlo Minetti; Philippe G Frank; Sergio A Jimenez; Erik S Knudsen; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

4.  Recapitulation of fibromatosis nodule by multipotential stem cells in immunodeficient mice.

Authors:  Jung-Pan Wang; Yun-Ju Hui; Shih-Tien Wang; Hsiang-Hsuan Michael Yu; Yi-Chao Huang; En-Rung Chiang; Chien-Lin Liu; Tain-Hsiung Chen; Shih-Chieh Hung
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

5.  SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression.

Authors:  Lu Wang; Zhaozhe Liu; Dongchu Ma; Ying Piao; Fang Guo; Yaling Han; Xiaodong Xie
Journal:  Cancer Cell Int       Date:  2013-08-29       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.